Blockade of CCL5 or its highest affinity receptor (CCR5) significantly attenuates the atherosclerosis process [67–69], as well as vascular inflammation in cases of lipodystrophy [70] and inflammation of perivascular adipose tissue (PVAT) in hypertension [66], as demonstrated in in vivo and in vitro studies. Here, CCL5 is linked to atherosclerosis.